Latest Market Research Updates: 2019

mHealth Apps Market Is Projected To Reach $236.0 Billion By 2026

The global mHealth apps market size is expected to reach USD 236.0 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 44.7% during the forecast period. The market is majorly driven by increasing adoption of advanced technologies in healthcare facilities and the need to reduce long waiting periods to access healthcare facilities from specialists.Availability of mobile applications for users is witnessing a rapid growth, especially healthcare apps that assist consumers in self-management of disease, wellness, and chronic conditions. This increased role of patients coupled with the rising importance in staying updated and informed about their own healthcare decisions, contributing to the rise in adoption of mHealth apps globally.

Healthcare industry has been transitioning towards a value-based care model with mHealth becoming a widespread trend owing to the advent of technologies such as remote monitoring, electronic medical record, and other communication platforms. The increasing prevalence of disorders, such as diabetes, hypertension, cancer, and obesity along with the growing awareness about wellness and other preventive measures diseases among patients is expected to boost the mHealth market growth.

mHealth leverages from the 4Ps: personalized, predictive, participatory, and preventive measures for care delivery to provide optimal care to users. Moreover, rising penetration of smartphones, and other electronic devices, especially, in low- and middle-income countries and increasing focus on the use of mobile technology to manage care delivery is anticipated to benefit the market.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/mhealth-app-market

Further key findings from the report suggest:

Rapid growth in chronic diseases along with the rise in the number of app users is accountable for the mHealth apps market growth
The types of mHealth apps include fitness, lifestyle management, nutrition and diet, women’s health, medication adherence, healthcare providers, and disease management. Of these, the fitness category accounted for the majority of segment share in 2018
mHealth app vendors are focusing their attention on women's health, diet, and medication reminders. According to Wired, a mobile advertising and analytics platform, women are more inclined toward tracking their health than men
Physicians are increasingly recommending the use of mHealth apps to their patients, which is likely to increase the adoption rate of mHealth apps
North America led the mhealth applications market in 2018 in terms of revenue share pertaining to the technological advancements and presence of major players in the region
Some of the key players are Johnson & Johnson; Abbott Laboratories; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Novartis AG; GlaxoSmithKline plc; Merck and Co., Inc.; Pfizer; and Sanofi

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com

Bone Grafts and Substitutes Market Is Projected To Reach $3.9 Billion By 2025

The global bone grafts and substitutes market size is expected to reach USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to register a healthy CAGR of 5.5% during the forecast period. Demand for bone grafts and substitutes is increasing due to adoption of newer technologies and increasing demand for minimally invasive procedures.

Availability of advanced products in varied shapes and sizes providing high osteoconductive and osteoinductive properties is supporting market growth. Moreover, growing adoption of minimally invasive procedures is spurring demand for bone grafts and substitutes. In minimally invasive procedures, large incisions and damage to muscles surrounding repair area can be significantly avoided. These techniques also reduce the duration of hospital stay and support rapid wound healing with lesser pain and surgical wounds. Minimally invasive total joint replacement and spine surgeries are some of the newly adopted procedures. Some of the companies in the bone grafts and substitutes market are DePuy Synthes; Medtronic PLC; Nuvasive, Inc.; Orthofix Holdings, Inc.; Wright Medical Group N.V.; AlloSource, Inc.; and Stryker Corp.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/bone-grafts-substitutes-market

Further key findings from the study suggest:

Increasing number of orthopedic surgeries and rising demand for minimally invasive surgeries are primary factors driving market growth
By material type, allografts accounted for the largest market share within the natural segment in 2016, mainly due to properties such as immediate structural support and osteoconductivity. Moreover, allografts do not require another surgery to harvest the bone, which results in reduced surgery time and wound healing, thus, attributing toward segment growth
North America is the leading regional market, followed by Europe. Rising awareness regarding commercially available products, higher healthcare expenditure, and availability of advanced healthcare infrastructure are prime factors responsible for the region’s expansion
Key players in the market include DePuy Synthes; Medtronic PLC; Nuvasive, Inc.; Orthofix Holdings, Inc.; Wright Medical Group N.V.; AlloSource, Inc.; and Stryker Corp.

About Grand View Research

Healthcare Staffing Market Is Projected To Reach $44.65 Billion By 2025

The global healthcare staffing market size is likely to reach USD 44.65 billion by 2025, based on a new report by Grand View Research, Inc., exhibiting a CAGR of 5.0% during the forecast period. Rising geriatric population is stirring up the demand for healthcare services around the globe. However, there is a shortage of efficient nurses and other healthcare professionals.

Shortage of physicians in developed regions is expected to bolster the growth of the healthcare staffing market. For instance, the Association of American Medical Colleges had predicted in 2010 that the U.S. is estimated to face a shortage of 150,000 doctors over the next 10 to 15 years. Furthermore, availability of skilled professionals at lower costs as and when required is anticipated to propel the market in the coming years.

Also, in response to pressure of costs, hospitals are forced to reduce their staff and have implemented policies to ensure that nurses would be available for work when workload increases. The healthcare staffing market has significant penetration and can easily provide staff during emergencies.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/healthcare-staffing-market

Further key findings from the study suggest:

The allied healthcare segment accounted for the largest revenue share in the market in 2018. It includes physical therapists, medical technologists, occupational therapists, respiratory therapists, pharmacists, and phlebotomists
The locum tenens segment is projected to witness the fastest growth during the forecast period. This can be attributed to cost-effectiveness for employers and increase in the number of physicians choosing to work as locum tenens
North America will lead the market through 2025 due to increasing geriatric population, lack of skilled professionals as compared to demand, and local presence of several market players
Asia Pacific is likely to experience the fastest growth during the next decade due to increasing investments by several market players, positive economic outlook, and rising awareness about contract staffing
Some of the key players are Envision Healthcare Corporation; AMN Healthcare; CHG Management, Inc.; Maxim Healthcare Services, Inc.; Cross Country Healthcare, Inc.; inVentiv Health; Almost Family; TeamHealth; and Adecco Group.

About Grand View Research

Population Health Management Market Is Poised To Reach $101.0 Billion By 2025

The global population health management market size is expected to reach USD 101.0 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 20.7% during the forecast period. The need for population health services that combine multiple functionalities is increasing, due to the complex nature of care delivery and payment models. PHM solutions can process clinical, financial, and operational data for the improvement of efficiency and patient care. The convenience offered by value-based payment models instead of Fee-for-Service (FFS) is responsible for increased adoption of these solutions by the Accountable Care Organizations (ACOs).

ACOs, consist of hospitals, clinics, doctors, and other caregivers, collaborate with payers for the delivery of high-quality patient care. Private and public insurance providers have introduced various disease management programs, to assist in the treatment of chronic illnesses. These multidisciplinary efforts are expected to result in effective treatment outcomes and are likely to suggest best suitable courses of action that need to be undertaken. Successful large-scale trials in U.S. have enabled significant advancements in disease management programs.

The market has a healthy mix of vendors offering PHM along with other healthcare IT solutions. Acquisitions and partnerships are the major strategies adopted by the companies operating in the population health management market. For instance, in 2018 Allscripts announced completion of acquisition of the HealthGrid Holding Company, a developer of enterprise patient engagement solution. The acquisition signifies expansion of the Allscripts FollowMyHealth platform that provides patient engagement solutions focused on connecting consumers with providers.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/population-health-management-phm-market

Further key findings from the report suggest:

Based on the products, the services segment held majority of the market share in 2018, as healthcare providers prefer in-house maintenance services
In 2018, healthcare provider held the largest market share of the end-use segment. The providers can focus effectively on patient-centric care and reducing overall costs
North America was the largest regional market in 2018 and is likely to retain its position over the forecast period, as the providers, payers, providers-payers, and accountable care organizations promote the use of PHM services
Asia Pacific is expected to witness the fastest growth in the forthcoming years due to rising healthcare expenditure and improving healthcare infrastructure
Allscripts, McKesson Corporation, and Cerner Corporation among others are some of the key players operating in the Population Health Management (PHM) market. Business partnerships and acquisitions are some of the key strategic initiatives undertaken by these companies to strengthen their market presence.

About Grand View Research

Home Infusion Therapy Market Is Projected To Reach $38.7 Billion By 2026

The global home infusion therapy market size is expected to reach USD 38.7 billion by 2026 registering a CAGR of 7.2% from 2019 to 2026, according to a new report by Grand View Research, Inc. Rapid technological advancements are some major factors contributing to the market growth. Home infusion is gradually being considered as an alternative to extended stay in hospitals or nursing homes for patients suffering from chronic diseases. With the administration of medications in home settings, patients recover faster, are more comfortable, and save money. Several government and non-government programs aimed at reducing the burden of hospital stays by establishing infusion centers that provide quick IV infusion services are likely to have a positive impact on the market.

Furthermore, favorable government policies and regulations are expected to propel the industry growth. In addition, rising prevalence of diseases, such as Cardiovascular Diseases (CVDs), cancer, diabetes, and other life-threatening conditions, is expected to be a high impact rendering driver for the market. According to the WHO, at present, all the aforementioned diseases account for 60% of total deaths and 43% of the disease burden in U.S. This creates the need to infuse nutritional products that contain glutamine, phospholipids, glucose, and amino acids, which in turn, is expected to boost the market growth in the region.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/home-infusion-therapy-market

Further key findings from the study suggest:

Infusion pumps led the product segment in 2018 owing to their extensive use for the delivery of fluids, such as medications and nutrients, during infusion therapy
Needleless connectors is the fastest-growing product segment over the forecast period. These devices provide protection from needlestick injuries
Anti-infective segment held the largest share in 2018 owing to a large number of procedures performed for administering antibiotics and antifungals
The chemotherapy segment is expected to witness lucrative growth during the forecast period on account of initiatives undertaken pertaining to cancer treatment, such as development of infusion centers by the Cancer Treatment Centers of America
The market is highly competitive and is marked by the presence of key companies, such as B. Braun Melsungen AG; ICU Medical, Inc.; Baxter; Fresenius Kabi AG; Caesarea Medical Electronics; Terumo Corporation; CareFusion Corporation; JMS Co. Ltd.; and Smiths Medical
Most of these companies focus on new product development to maintain their position in the global home infusion therapy market

About Grand View Research

Biosensors Market Is Projected To Reach $33.76 Billion By 2026

The global biosensors market size is anticipated to reach USD 33.76 billion by 2026 registering a CAGR of 8.1%, according to a new report by Grand View Research, Inc. Various applications in the medical field, high demand for miniature diagnostic devices, and rapid technological advancements are the key driving factors for biosensors market growth. Early and precise disease diagnosis is essential for successful prognosis of diseases and survival of patients. In recent years, the demand for simple, disposable, user-friendly, and cost-efficient devices with fast response time has increased extensively leading to increase in the sales of these products, thereby driving the market.

Continuous technological developments are also expected to boost the market. For instance, in October 2015, Abbott Laboratories launched FreeStyle Libre Glucose Monitoring System in Europe. It is intended to be a replacement for blood glucose meters. Moreover, rising applications of thermal biosensors in biomolecular interaction and hybridization analysis, environmental monitoring, and cosmetic analysis are expected to boost the biosensors market growth. In addition, the development of nano particle-based electrochemical biosensors is expected to create growth opportunities for the key comapnies, thereby driving the market.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/biosensors-market

Further key findings from the study suggest:

Medical application segment led the market in 2018. Medical wearable biosensors are considered an essential tool in the detection and monitoring of a wide range of medical conditions, such as diabetes and cancer
Electrochemical biosensors accounted for the largest market share in 2018 and are anticipated to witness a significant growth over the forecast period
This growth can be attributed to its widespread applications for quantification and analysis in biochemical and biological processes
On the basis of end use, biosensors in food industry are expected to witness a rapid growth owing to rising pressure from regulatory bodies pertaining to the hygiene standards of the food items where this device plays a vital role for detecting pathogens, allergens, and pesticides
Asia Pacific market is expected to witness the fastest growth over the forecast period owing to increasing awareness regarding wearable biosensors and constantly improving healthcare facilities in the region
Key companies in the market includes AZUR Environmental; Abbott Laboratories; Biosensor BV; Bayer AG; Cranfield Biotechnology Centre; DuPont Biosensor Materials; Ercon, Inc.; and Johnson & Johnson

About Grand View Research

Neurorehabilitation Devices Market Is Projected To Reach $3.2 Billion By 2024

The global neurorehabilitation devices market in 2015 was valued at USD 915.1 million and is estimated to reach USD 3.2 billion by 2024. Around 1 billion people are suffering from neurological disorders across the globe. These neurological disorders are resulting in increased movement disabilities. The increasing prevalence of movement disability, attributed to various neurological disorders (multiple sclerosis, stroke, etc) along with need for comprehensive management is the key factors driving the market growth.

Every year around 15 million people suffer from stroke globally, of which 5 million people are affected by permanent disability. Each year Multiple sclerosis and Parkinson’s disease affect 2.5 million and 10 million patients respectively worldwide. The increasing prevalence and incidence rates of neurological disorders create a huge demand for neurorehab devices, as they ensure simplification of routine tasks for the disabled patients by reducing their dependency on others.

Furthermore, the rising awareness of neurorehab services among the care providers is contributing to the increasing adoption of these devices. In addition, consistent technological advancements are leading to introduction and commercialization of novel products in this sector. Majority of the manufacturers and distributors of neurorehab platforms are headquartered in North America region. North America dominates the market followed by Europe attributed to the rising awareness and increased adoption of novel technologies in these regions. Asia Pacific is growing at the highest CAGR among all the regions due to increasing target population and improving healthcare infrastructure.

Despite fluctuating economic conditions across different geographical regions coupled with the respective regulatory pressures, the companies offering neurorehab devices and services are exhibiting adaptability and efficacy. Some of the key market players are Bioness, Inc., Ectron Ltd., Hocoma AG, Medtronic, and Tyromotion. Collaborations for novel product development and strengthening of distribution networks constitute some of the strategic initiatives implemented by key players. For instance, Ectron Ltd. has collaborated with Bioness, Inc. and Tyromotion for distribution of their products across different geographical regions.

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/neurorehabilitation-devices-market

Further Key Findings from the Study Suggest:

Neurorobotics is expected to be one of the most lucrative segments in the coming years owing to the high availability of exoskeletons and prosthetics targeted for treating movement disabilities. Bioness, Inc. and Hocoma AG are few of the key manufacturers of exoskeletons and prosthetics.
Consistent technological sophistications in brain stimulations and machine learning brain-computer interface segment is expected to develop tremendously.
Non invasive stimulators have the potential to modulate brain plasticity. In February 2016, USFDA approved Medtronic’s brain stimulation therapy in the treatment of Parkinson’s disease.

About Grand View Research

Orthopedic Device Market Total Revenue Would Be $47.7 Billion By 2026

The global orthopedic device market size is expected to reach USD 47.7 billion by 2026, according to the study performed by Grand View Research, Inc. It is anticipated to expand at a CAGR of 3.1% over the forecast period. Major factors driving the market include high demand for orthopedic surgeries owing to rising incidents of road accidents and prevalence of orthopedic diseases.

Rise in geriatric population prone to orthopedic conditions is primarily pushing the demand for orthopedic solutions globally.Effects of aging such as lowering of bone density and weakening of bones due to excessive loss of bone mass is prominent in people from 25 to 54 years age group that become more noticeable after 55 years.

High adoption of minimally invasive surgeries and increasing number of sports and road traffic accidents are expected to fuel growth of the orthopedic devices market growth during the forecast period. Arthroscopy, minimally invasive total joint replacement, and spine surgeries are some of the newly adopted minimally invasive surgeries.

Stringent procedures of regulatory approvals are anticipated to hinder market growth in near future. In addition, high cost of devices and surgeries are some other factors likely to impede the growth.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/orthopedic-devices-market

Further key findings from the study suggest:

Knee orthopedic devices captured the largest market share in 2017 attributed to rise in knee surgeries including common knee injuries and total knee replacements
North America captured the largest market share in 2017 and is expected to continue leading over the forecast period. The presence of a large number of major market players and high adoption of advanced technologies are the major driving factors
Asia Pacific is expected to exhibit a lucrative CAGR during the forecast period. The presence of a large untapped market and supportive government regulations are expected to attract attention of the global market players
Some of the major players in the orthopedic devices market include NuVasive, Inc.; Medtronic PLC; Zimmer-Biomet Holdings; DePuy Synthes; Stryker; Aesculap Implant Systems, LLC; Donjoy, Inc.; and Conmed Corporation.

About Grand View Research

Antibody Drug Conjugate Market Is Projected To Reach USD 9.93 Billion By 2025

The global antibody drug conjugate market size is expected to reach USD 9.93 billion by 2025, according to a new report by Grand View Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.

Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.

Seattle Genetics and Roche are leading the antibody drug conjugate market in terms of market share. Until 2017 only two ADCs were commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche. Recently, two more Pfizer’s products were approved to be marketed for acute myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been estimated that over the forecast period, Pfizer is anticipated to gain a significant market share.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

Further key findings from the report suggest:

Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer
Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market
In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market
The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

About Grand View Research

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: sales@grandviewresearch.comFor More Information: www.grandviewresearch.com

Injection Pen Market Is Estimated To Generate $67.9 Billion By 2025

The global injection pens/injectable pens/pen injectors market is expected to reach USD 67.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 9.4% CAGR during the forecast period. High demand for these devices for management of various chronic as well as acute diseases and increasing awareness in developing regions are key factors expected to drive the market.

Injectable pens have witnessed significant success in improving patient convenience during management of chronic disease, a process that might include administering intermittent injections. These devices are more convenient and affordable than other delivery systems. Ongoing studies on the same to assess their applications in management of other diseases, including but not limited to Hepatitis C and cancer, is expected to ensure swift market growth through 2025.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/injection-pens-market

Further key findings from the study suggest:

Rising incidence of diseases such as diabetes and arthritis is primarily boosting market growth
Increase in government healthcare expenditure and availability of favorable healthcare insurance policies in developed as well as developing countries is driving the market
By product, reusable injectable pens are the largest and fastest growing segment owing to the advantages associated with them such as cost effectiveness and patient convenience. Commercially available reusable injectable pens mainly include Novopen, Luxura, Berlipen, AllStar, NovoRapid, basalgar, Bydureon, Epipen and Genotropin
By dosage, variable dosage is the fastest growing segment. Some of the customizable variable pens are UnoPen, ServoPen and Ypsopen by Ypsomed, Madie by SHL Group, and Evo pen by Copernicus
North America dominates the market, followed by Europe. Technological advancements and increase in incidence of osteoporosis, arthritis, and anaphylaxis are factors that can be attributable to its largest market share
Asia Pacific is expected to be the fastest growing region over the forecast period. Better accessibility to healthcare, coupled with constantly increasing healthcare expenditure in the region, is fueling market growth
China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players. This is owing to favorable factors such as availability of labor and raw materials at significantly lower prices as compared to other regions
Key players in the market include Owen Mumford Ltd.; GlaxoSmithKline plc; Eli Lilly and Company; Mylan N.V.; AstraZeneca; Novo Nordisk; Sanofi; and Sandoz Inc.

About Grand View Research

Protein Engineering Market Is Projected To Reach $3.09 Billion By 2025

The global protein engineering market is expected to reach USD 3.09 billion by 2025, according to a new report by Grand View Research, Inc. The market is driven by presence of regulatory authorities consistently striving to reduce time and cost involved in the drug discovery process. One such example is the launch of critical path initiative by U.S. FDA, for incorporation of advanced technologies, such as protein engineering, in drug discovery processes. Moreover, this facilitates prediction of probable adverse reactions & toxicity and improves efficacy of target molecules early on, resulting in lowered drug attrition rates in the later stages. This is anticipated to help control overall expenditure. Rise in R&D expenditure by countries indicates the urgent need for adoption of these tools in all drug discovery and development processes.

The rising number of government initiatives aimed at enhancing protein engineering capabilities is anticipated to present the market with high growth potential. This has resulted in a significant rise in number of research activities & programs and fund allotment for R&D. For instance, Protein Engineering Network of Centres of Excellence (PENCE) contributed approximately USD 1.0 million for proteomics projects and hosted conferences on proteomics in Canada as an effort to broaden research associated with this technology.

To request a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/protein-engineering-market

Further Key Findings From the Report Suggest:

Hybrid approach is predicted to observe exponential growth as a consequence of technological superiority and ability to overcome the shortcomings associated with the aforementioned technologies
Software & services is expected to emerge as the fastest growing segment owing to high inclination of companies to outsourcing of services to achieve overall cost-efficiency
Monoclonal antibodies held the largest share in protein-type segment due to development of these antibodies on a large scale through extensive adoption of these engineering tools
North America held a substantial share, which can be attributed to extensive research activities that are likely to provide high potential growth platform through consistent usage in this region
The market in Asia Pacific is projected to exhibit exponential growth over the coming years owing to rising awareness pertaining to benefits of protein engineering and increasing disposable income
The competition is marked by players employing strategies such as mergers & acquisitions and distribution agreements resulting in significant growth in their market share

About Grand View Research

Contact:Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
For More Information: www.grandviewresearch.com

Mouth Ulcers Treatment Market is Projected To Reach $1.32 Billion By 2026

The global mouth ulcers treatment market size is projected to reach USD 1.32 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 3.8% during the forecast period. Increasing geriatric population and rising awareness towards oral hygiene are among the key trends stimulating market growth.

Growing global geriatric population is poised to trigger the number of cases of mouth ulcers. As per the findings of the United Nations Organization (UNO), population base of age 60 years or older across the globe was 962.0 million in 2017, which was more than twice as large as in 1980, when the population was 382.0 million. With upswing in the demand for denture fittings in this population, rise in the incidences of improper fittings and deficiency of vitamin B & folic acid is anticipated. Such incidents can lead to mouth ulcers.

Newly fitted dentures takes some time to adjust. During the procedure, inner area of the mouth remains moist for a certain period. Such conditions favor fungal infection leading to ulcer. Older population often suffer from such conditions, due to which they are prone to oral problems. In addition, deficiency of vitamins is a common phenomenon observed among geriatric population, which also increases the probability of suffering from mouth ulcer.

Rising awareness regarding oral hygiene in developing countries is also estimated to drive the market over the forecast period. Campaigns on oral hygiene in rural areas of developing countries are working in favor of the market. For instance, every year, Colgate-Palmolive Company conducts an oral health month in rural areas of India in order to impart awareness regarding oral hygiene. Such initiatives are expected to encourage people to take up necessary treatments. Furthermore, rise in tobacco usage in countries such as U.K. and Mexico is projected to boost the rate of mouth ulcers, thereby benefitting the growth of the market.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/mouth-ulcers-treatment-market

Further key findings from the report suggest:

Analgesics and Corticosteroids are poised to exhibit the highest CAGR during the forecast period. These are the most prescribed drugs by doctors and are easily available
By 2026, Asia Pacific is likely to dominate the mouth ulcer treatment market with a share of around 63.0%. Increasing awareness pertaining to oral hygiene and treatment and rising prevalence of aphthous ulcers are likely to supplement the growth of the market
Some of the key companies present in the market are Blistix Inc., Church & Dwight Co., Inc., 3M, Colgate-Palmolive Company, Pfizer, Bristol-Myers Squibb (BMS), and others are expected to dominate the market over the forecast period.

About Grand View Research

Acne Drugs Market Is Projected To Reach $5.9 Billion By 2025

The global acne drugs market size is expected to reach USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 4.2% CAGR during the forecast period. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.

Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2017, and it is expected to continue this trend through 2025. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.

By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.

Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.

Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/acne-drugs-market

Further key findings from the report suggest:

By type, inflammatory acne captured more than 50.0% of the market in 2017. Comedonal acne were ranked second-largest, among other types
On the basis of therapeutic class, retinoids led the market in 2017, followed by antibiotics. This trend is likely to continue through 2025
The treatment paradigm is shifting toward combination therapies and biologics. Combination products are gaining traction due to higher efficacy, convenient dosing, and fewer adverse effects
Topical products dominated the treatment landscape, based on mode of administration. However, introduction of biologics is likely to result in the growth of the injectables segment
S. dominated the major markets and is projected to maintain its lead through 2025, owing to rising disease incidence and ease of access to anti-acne products
Allergan, Bayer, Galderma, Stiefel, and Valeant are some key players operating in this market. Valeant is projected to lead the market in 2025 due to higher adoption of Retin-A micro as well as anticipated launch of pipeline candidates.

About Grand View Research

Antibody Drug Conjugate Market Is Poised To Reach USD 9.93 Billion By 2025

To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

Further key findings from the report suggest:

Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer
Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market
In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market
The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

About Grand View Research

Latest Market Research Updates

mHealth Apps Market Is Projected To Reach $236.0 Billion By 2026

Bone Grafts and Substitutes Market Is Projected To Reach $3.9 Billion By 2025

Healthcare Staffing Market Is Projected To Reach $44.65 Billion By 2025

Population Health Management Market Is Poised To Reach $101.0 Billion By 2025

Home Infusion Therapy Market Is Projected To Reach $38.7 Billion By 2026

Biosensors Market Is Projected To Reach $33.76 Billion By 2026

Neurorehabilitation Devices Market Is Projected To Reach $3.2 Billion By 2024

Orthopedic Device Market Total Revenue Would Be $47.7 Billion By 2026

Antibody Drug Conjugate Market Is Projected To Reach USD 9.93 Billion By 2025

Injection Pen Market Is Estimated To Generate $67.9 Billion By 2025

Protein Engineering Market Is Projected To Reach $3.09 Billion By 2025

Mouth Ulcers Treatment Market is Projected To Reach $1.32 Billion By 2026

Acne Drugs Market Is Projected To Reach $5.9 Billion By 2025

Antibody Drug Conjugate Market Is Poised To Reach USD 9.93 Billion By 2025

mHealth Apps Market Is Projected To Reach $236.0 Billion By 2026

Report Abuse

Labels